key: cord-0760542-blbemp67
authors: Jalkanen, Pinja; Pasternack, Arja; Maljanen, Sari; Melén, Krister; Kolehmainen, Pekka; Huttunen, Moona; Lundberg, Rickard; Tripathi, Lav; Khan, Hira; Ritvos, Mikael A; Naves, Rauno; Haveri, Anu; Österlund, Pamela; Kuivanen, Suvi; Jääskeläinen, Anne J; Kurkela, Satu; Lappalainen, Maija; Rantasärkkä, Kaisa; Vuorinen, Tytti; Hytönen, Jukka; Waris, Matti; Tauriainen, Sisko; Ritvos, Olli; Kakkola, Laura; Julkunen, Ilkka
title: A combination of N and S antigens with IgA and IgG measurement strengthens the accuracy of SARS-CoV-2 serodiagnostics
date: 2021-04-27
journal: J Infect Dis
DOI: 10.1093/infdis/jiab222
sha: b24fd4be9ce4e1ee2f306872593a0b1d1355005a
doc_id: 760542
cord_uid: blbemp67

BACKGROUND: The primary diagnosis of SARS-CoV-2 infection is based on the detection of virus RNA in nasopharyngeal swab samples. In addition, analysis of humoral immunity against SARS-CoV-2 has an important role in viral diagnostics and seroprevalence estimates. METHODS: We developed and optimized an enzyme immunoassays (EIA) using SARS-CoV-2 nucleoprotein (N), S1 and receptor binding domain (RBD) of the viral spike protein, and N proteins from SARS, MERS, and four low-pathogenic human CoVs. Neutralizing antibody activity was compared with SARS-CoV-2 IgG, IgA and IgM EIA results. RESULTS: The sensitivity of EIA for detecting immune response in COVID-19 patients (n=101) was 77 % in the acute phase and 100 % in the convalescent phase of SARS-CoV-2 infection when N and RBD were used as antigens in IgG and IgA specific EIAs. SARS-CoV-2 infection significantly increased humoral immune responses against the 229E and NL63 N proteins. S1 and RBD-based EIA results had a strong correlation with microneutralization test (MNT) results. CONCLUSIONS: The data indicate that a combination of SARS-CoV-2 S1 or RBD and N proteins and analysis of sera in IgG and IgA immunoglobulin classes provide an excellent basis for specific and sensitive serological diagnostics of COVID-19.

A c c e p t e d M a n u s c r i p t 4 

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), causing COVID-19, emerged in December 2019 [1] and the outbreak was declared as a pandemic by WHO in March 2020 [2] . By December 2020, the pandemic had resulted in nearly 3 million deaths and 140 million confirmed cases (https://coronavirus.jhu.edu/map.html). SARS-CoV-2 is closely related to two coronaviruses causing severe respiratory infections in humans, SARS-CoV and Middle East respiratory syndrome (MERS) CoV, of which SARS-CoV shares 79 % sequence identity with SARS-CoV-2 [3] . MERS-CoV, SARS-CoV, and SARS-CoV-2 belong to genus Betacoronavirus along with two other human coronaviruses (HCoVs) OC43 and HKU1, which cause milder respiratory infections. The other two low-pathogenic HCoVs, 229E and NL63, belong to genus Alphacoronavirus [4] .

To diagnose an acute SARS-CoV-2 infection, viral RNA is detected in the nasopharyngeal swab sample by RT-qPCR. To survey past infections and to assess immunological responses, a variety of serological assays are available [5] . Most of the serological assays are based on the recognition of IgG and IgM antibodies against SARS-CoV-2 nucleoprotein (N), spike protein (S), or receptor binding domain (RBD) of S, while the detection of IgA antibodies has remained less utilized [6] [7] [8] [9] [10] . Antibody assays show remarkable discrepancies [7, 11] and COVID-19 patient sera have been shown to react to low-pathogenic HCoV S antigens [12] . Detailed analysis of serological cross-reactivity against SARS-CoV-2 antigens is still missing and relying on just one of the commonly used viral antigens or immunoglobulin classes may give inaccurate results.

In this study, we have developed SARS-CoV-2 N and S protein-based enzyme immunoassays (EIA) and measured serum anti-SARS-CoV-2 IgG, IgA, and IgM antibodies in COVID-19 patients. We have evaluated the cross-reactivity of antibodies against MERS, SARS, and four low-pathogenic HCoV nucleoprotein antigens. We demonstrate that previous infections with low-pathogenic HCoVs can cause some antibody cross-reactivity with the antigens of high-pathogenic coronaviruses and that SARS-CoV-2 infection can boost low-pathogenic HCoV antibody production. For reliable analysis of herd immunity and serodiagnosis of an acute or a recent infection, IgG and IgA antibody determination for both SARS-CoV-2 N and S antigens is necessary.

A c c e p t e d M a n u s c r i p t 5 [14] and used as a negative control in EIAs. GeneArt. Genes were cloned into pBVboost plasmid with N-terminal glutathione S-transferase (GST) and proteins were produced in Spodoptera frugiperda (Sf-9) cells and purified as described earlier [15] . Protein purity and concentration were estimated with sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and Page Blue (Thermo Fischer Scientific) staining with known amounts of bovine serum albumin (BSA) protein as standards.

Production and purification of recombinant SARS-CoV-2 spike protein S1 and RBD antigens SARS-CoV-2 sequence was obtained from GenBank (MN908947.3). Codon optimized cDNAs representing S1 (amino acid residues 16-541) and RBD (amino acid residues 319-541) were obtained from GeneUniversal. For production of a negative control antigen a cDNA (GeneUniversal) encoding A c c e p t e d M a n u s c r i p t 6 mouse myostatin growth factor pro-region (amino acid residues 1-263, with a D76A stabilizing mutation; GenBank accession AAI05675) fused to a GSGGGG linker and a mouse IgG2a Fc part (amino acid residues 238-469) tagged with a C-terminal polyhistidine tail was used to encode proMstn-mFc(IgG2a)-6xHis . S1 and RBD cDNAs were subcloned with C-terminal 8xHis tag (monomeric) or mouse IgG2a Fc tag into a mammalian expression plasmid vector with a CAGpromoter and internal ribosomal entry site (IRES) driven puromycin selection gene. Expression plasmids were transfected to human embryonic kidney (HEK293F) and Chinese hamster ovary (CHO-S) cells with Fugene 6 (Promega) and selected for stable cell production with puromycin (Gibco) as described [16] . For a large scale production, the cell lines were adapted to suspension culture in CD OptiCHO medium (Gibco) supplemented with 2 mmol/l Ultraglutamine (Lonza).

Cultures were maintained in square bottom glass flask cultures at 37°C, and subsequently transferred to 33°C for 5-8 days for protein production. Media was harvested, passed through 0.22-µm membrane 

Enzyme immunoassay (EIA) was done as described previously for other viral antibody determinations [17] . For coronavirus-specific antibody EIA 96-well microtiter plates (Nunc Maxisorp, Thermo Fisher Scientific) were coated with 50 µl of GST-N (2.0 µg/ml), RBD-mFc-8xHis (4.2 µg/ml), and S1-mFc-6xHis (3.0 µg/ml) in PBS at 4°C overnight. GST (0.7 µg/ml) and proMstn-mFc-6xHis (4.2 µg/ml) proteins were used as negative control antigens. After coating, the plates were washed once with 

MNT was performed as described previously [18] with some modifications. Briefly, serum samples were serially diluted two-fold from 1:10 to 1:5120 in 2% FCS in DMEM in a 96-well cell culture plates and 1000 TCID 50 of SARS-CoV-2 isolate Finland/1/2020 (GenBank accession number MT020781.2) was added to the serum dilutions. The mixtures were incubated at 37°C for 1 hour, VeroE6 cells (50 000 cells/well) were added and the plates were incubated at 37°C. Cytopathic effect was observed after 3 days. Serum dilutions were done in triplicates and the neutralizing antibody titer was calculated as a 50 % endpoint of the serum dilution that inhibited the SARS-CoV-2 infection in at least two parallel wells.

Receiver operating characteristics (ROC) analysis was done with GraphPad Prism 8 software to determine the cut-off EIA unit values for IgG, IgA, and IgM EIA assays. Statistical differences in antibody levels between the groups were analyzed with one-way ANOVA followed by Tukey's multiple comparisons test. Correlation coefficient determinations and graphs were done with GraphPad Prism 8 software and adjusted p-values of <0.05 were considered statistically significant.

A c c e p t e d M a n u s c r i p t 8 

SARS-CoV-2 N and S proteins are the most promising candidates for serological assays. N protein is weakly conserved between low-pathogenic and high-pathogenic coronaviruses (24.4-35.5 % amino acid identity, Table 1 ) whereas the similarity in the S1 and RBD parts of S protein is lower (8-18 % amino acid identity, Table 1 ).

To select optimal spike-protein antigen(s) for EIA, the performance of RBD and S1 proteins with and without mFc-fusion were analyzed ( Supplementary Fig. 1 ). RBD-6xHis from Florian Krammer [19] was used as a reference antigen. Reference and our His-tagged RBD antigens showed equal IgG, IgA, and IgM responses, whereas RBD coupled to mFc showed higher antibody binding signals. S1

showed a higher signal than either one of the RBD constructs and coupling of S1 to mFc further increased the antibody signals. Control antigen, proMstn-mFc, showed very low levels of reactivity.

Based on these results, RBD and S1 coupled to mFc were chosen for antigens in EIA. The use of mFc fusion in the HEK293 expression system yielded higher production levels of the recombinant protein compared to monomeric molecules or the CHO expression system. All antigens used in EIA were expressed and purified to a relatively high level ( Supplementary Fig.   1 ). To validate our EIA assay, we tested the reactivity of three COVID-19 patient paired serum samples and four control samples with recombinant SARS-CoV-2 GST-N, S1-mFc, and RBD-mFc proteins. Of the paired serum samples, the first samples were collected within 1 to 4 days after a positive PCR-test result and the second samples were collected 2 to 14 days after the first sample collection. All three patients showed an increase in the IgG antibody levels between the first and the second samples for all three antigens (Fig. 1) . Negative control antigens, GST and proMstn-mFc, showed a very low level of reactivity. To select an optimal serum dilution for EIA, serum samples were tested in different dilutions for IgG responses for the three antigens (Fig. 1) . The background signals were low in serum dilutions of 1:300 or higher, and therefore, the serum dilution of 1:300 was chosen for EIA. 

Next, we evaluated the potential cross-reactivity of SARS-CoV-2 infection-induced antibodies against different coronavirus N proteins. SARS-CoV-2 anti-N IgG, IgA, and IgM antibodies were highly cross-reactive with SARS-CoV N protein but only weakly cross-reactive with MERS-CoV N protein (Fig. 2) . We also detected weakly cross-reactive IgG, IgA, and IgM antibodies in some of the control group specimens against SARS-CoV (2-5 %) and MERS-CoV (3-5 %) N proteins (Fig. 2, Table 2 ).

The same serum samples had variable levels of antibodies against low-pathogenic HCoV N proteins.

Based on the IgG EIA, in the control group, the seroprevalence of HCoV-HKU1 and HCoV-OC43 was 27 and 45 %, respectively, and for HCoV-229E and HCoV-NL63 was 69 and 86 %, respectively ( Table 2 ). As expected, IgA and IgM antibodies were less prevalent (seroprevalence of 3-4 % for HCoV-HKU1, 1-9 % for HCoV-OC43, 8-9 % for HCoV-229E, and 6-22 % for HCoV-NL63).

Interestingly, N protein-specific IgG antibody levels against HCoV-229E and HCoV-NL63 Nproteins were significantly higher in the acute and especially in the convalescent phase group compared to the control group ( Fig. 2A) . However, significantly higher antibody levels were not observed in IgA or IgM antibodies ( Fig. 2B and 2C) . 

In addition to the N protein-based EIA, serum samples were tested with SARS-CoV-2 S1-mFc and RBD-mFc antibody EIAs. The cut-off units were determined with ROC curve analysis by choosing 98 %, 99 %, and 100 % specificity for anti-S1 IgG, IgA, and IgM EIA, and 99 %, 100 %, and 99 % specificity for anti-RBD IgG, IgA, and IgM EIA, respectively ( Supplementary Fig. 2 ). In the acute phase group, IgG antibodies against RBD and S1 were found in 49 % (45/92) and 41 % (38/92) of samples, respectively. IgA and IgM seropositivity was 65 % (56/92) and 58 % (53/92) against RBD, and 57 % (52/92) and 49 % (45/92) against S1, respectively ( Table 3 ). The arithmetic mean IgG, IgA, and IgM antibody levels against RBD and S1 were similar and the mean antibody levels were significantly higher in the convalescent phase group as compared to the acute phase group specimens ( Fig. 3) .

To analyze whether the EIA results of three SARS-CoV-2 antigens correlate, we compared the antibody responses against S1 and RBD to those of N protein-specific responses. Antibody responses against SARS-CoV-2 N and S1 proteins had a moderate to strong positive correlation (IgG r=0.81, IgA r=0.67, and IgM r=0.64) as well as antibody responses against N and RBD proteins (IgG r=0.85, IgA r=0.71, and IgM r=0.66). Antibody responses against S1 and RBD showed a very strong positive correlation (IgG r=0.96, IgA r=0.96, and IgM r=0.95) (Supplementary Fig. 4 ).

Next, we analyzed the combined results of anti-N, anti-S1, and anti-RBD IgG, IgA, and IgM EIAs.

When the results of anti-N IgA measurement were combined with the results of anti-S1 or anti-RBD IgA measurement, the sensitivity increased in the acute phase group from 63 % for anti-N IgA to 70 % for anti-N+S1 IgA and to 75 % for anti-N+RBD IgA combination (Table 3) . A combination of anti-N and anti-S1 or anti-RBD IgG antibody data to IgA antibody data increased the sensitivity from 69 % for anti-N IgA/IgG to 72 % for anti-N+S1 IgA/IgG combination and to 77 % for anti-N+RBD IgA/IgG combination. Similarly, a combination of anti-N and anti-S1 or anti-RBD IgA and IgM A c c e p t e d M a n u s c r i p t 12 antibody measurement increased the sensitivity in the acute phase group from 66 % for anti-N IgA/IgM to 72 % for anti-N+S1 IgA/IgM combination and to 80 % for anti-N+RBD IgA/IgM combination. In the convalescent phase group, a combination of anti-N and anti-RBD IgA showed sensitivity of 100 %. Overall, these results indicate that IgA is important in the serological SARS-CoV-2 diagnosis in the acute phase, and both N and S proteins (S1 or RBD) are needed for accurate serological testing.

Next, we analyzed the correlation of SARS-CoV-2 N and S protein (S1 and RBD) specific immune responses in EIA with neutralizing antibodies (MNT). Altogether, 119 COVID-19 patient serum specimens were analyzed of whom 68 samples had been determined before [7] . MNTs performed in different laboratories used the same virus isolate and the results correlated very well (n=18, r 2 >0.9, data not shown). Altogether, anti-S1 and anti-RBD IgG, IgA, and IgM antibody levels correlated strongly with MNT results (r>0.76) (Fig. 4) . The highest correlation was with anti-S1 IgG and IgM EIA (r=0.86). In addition, anti-N IgG, IgA, and IgM antibody levels correlated well with neutralizing antibody titers (r=0.79, r=0.65, and r=0.63, respectively), although the correlation was weaker than with anti-S1 or anti-RBD antibodies.

Sensitive and specific detection of antibodies against SARS-CoV-2 proteins is critical for early and accurate serological diagnostics and to estimate the rate of past infections or herd immunity in epidemiological studies. Our data support the idea that using both N and S1/RBD antigens in SARS-CoV-2 antibody detection is beneficial. We demonstrated that by combining anti-N and anti-RBD IgA with IgM or IgG EIA measurement, a rather high sensitivity (77-80 %) was reached within the first two weeks of SARS-CoV-2 infection. In the convalescent phase, the measurement of anti-N and anti-RBD IgA antibodies resulted in 100 % sensitivity. In addition, we show that creating mFc fusion S1

A c c e p t e d M a n u s c r i p t 13 and RBD domains increases the yield in protein production and the signals in EIA potentially increasing the sensitivity of the assays.

Recent studies have shown that anti-RBD IgA antibodies are short-lived and persist up to two months after the onset of symptoms [23, 24] supporting the use of IgA antibody determination in identifying an acute/recent SARS-CoV-2 infection. For epidemiological studies, anti-N and anti-S IgG antibodies are important since they have been shown to persist for longer periods of time [23, 25] . Dual measurement of IgA and IgG antibodies provides a reliable assay for determining COVID-19 incidence in low antibody prevalence populations.

The presence of anti-S1 and anti-RBD IgG, IgA, and IgM antibodies in serum correlated well with viral neutralizing activity. Recent studies have reported similar results, and both anti-S1 and anti-RBD IgG and IgM antibodies have been shown to correlate with neutralizing antibody activity [11, 25, 26] .

Unlike anti-S1 and anti-RBD antibodies, anti-N antibodies are likely not neutralizing, and indeed, we did not find as strong correlation between anti-N antibodies and neutralizing antibody titers as with anti-S1 and anti-RBD antibodies. It is noteworthy that not all anti-S1 and anti-RBD antibodies are neutralizing [27] , however, it may be possible to identify anti-spike antibody levels in EIA that would relatively well correlate with protective immunity, enabling population level estimates of anti-SARS-CoV-2 immunity.

HCoV-229E and HCoV-NL63 in patients who had low or even undetectable pre-existing antibodies against corresponding low-pathogenic HCoVs. These responses could be due to cross-reactive epitopes or activation of memory B cells from previous coronavirus infections. Similar results have been observed in SARS patients who experienced an increase in the antibody levels against HCoV-229E, HCoV-NL63, and HCoV-OC43 between an acute and convalescent phase of SARS-CoV infection [28, 29] .

We did not detect any significant cross-reactivity against SARS-CoV-2 N and S1/RBD proteins in the serum specimens of the control group, and thus SARS-CoV-2 N, S1, and RBD-based EIA assays had A c c e p t e d M a n u s c r i p t 14 very high specificity (98-100%). However, we detected some individuals with low-level crossreactive anti-N IgG, IgA, or IgM antibodies against other high-pathogenic HCoVs, SARS-CoV and MERS-CoV. This could be due to previous low-pathogenic HCoV infections since antibodies against low-pathogenic HCoVs were highly prevalent in control individuals and the sequence identity between MERS and low-pathogenic HCoV N proteins ranged from 24 to 36% (data not shown). As a whole, our results are well in line with previous studies showing very low rate of antibody crossreactivity in pre-COVID-19 pandemic individuals to N and S1 proteins of SARS-CoV-2 [8, 30, 31] .

Here we have demonstrated that the dual measurement of IgG and IgA antibodies targeting nucleoprotein and spike protein domains of SARS-CoV-2 provide increased sensitivity in serological testing. Information on the cross-reactivity of HCoVs is crucial for accurate diagnosis and determining the level of pre-existing immunity against SARS-CoV-2 infections. The use of other SARS-CoV-2 proteins apart from structural proteins may also provide a special advantage in increasing the sensitivity of diagnostic tests or seroprevalence studies. In addition, the use of nucleoprotein and immunogenic nonstructural SARS-CoV-2 proteins as antigens in serological assays may provide the means to differentiate natural infection from vaccine-induced immunity enabling the estimation of true vaccine efficacy against COVID-19 infection. We still have a long way to a full understanding of COVID-19 immunity.

A c c e p t e d M a n u s c r i p t 15 M a n u s c r i p t A c c e p t e d M a n u s c r i p t 22 Table 1 Comparison of N, S1 and RBD protein amino acid sequence identity. Table 3 Sensitivity (%) of SARS-CoV-2 N-, S1-and RBD-based EIA.

N S1 RBD N + S1 N + RBD A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t 

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Listings of WHO's response to COVID-19

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

Genetic Recombination, and Pathogenesis of Coronaviruses

Evaluation of Nucleocapsid and Spike Protein-Based Enzyme-Linked Immunosorbent Assays for Detecting Antibodies

Performance of six SARS-CoV-2 immunoassays in comparison with microneutralisation

Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease ( COVID-19 )

Antibody responses to SARS-CoV-2 in patients with COVID-19

Serum IgA, IgM, and IgG responses in COVID-19

An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment

Cross-Sectional Evaluation of Humoral Responses against SARS-CoV-2 Spike

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

Serological Array-in-Well Multiplex Assay Reveals a High Rate of Respiratory Virus Infections and Reinfections in Young Children

Production, purification and immunogenicity of recombinant Ebola virus proteins − A comparison of Freund's adjuvant and adjuvant system 03

Muscle protein synthesis, mTORC1/MAPK/Hippo signaling, and capillary density are altered by blocking of myostatin and activins

Pandemic influenza A(H1N1pdm09) vaccine induced high levels of influenza-specific IgG and IgM antibodies as analyzed by enzyme immunoassay and dual-mode multiplex microarray immunoassay methods

Serological and molecular findings during SARS-CoV-2 infection: The first case study in Finland

A serological assay to detect SARS-CoV-2 seroconversion in humans

SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood

Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019

Distinct features of SARS-CoV-2-specific IgA response in COVID-19 patients

Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients

Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients

Robust neutralizing antibodies to SARS-CoV-2 infection persist for months

The receptor-binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients

Linear epitopes of SARS-CoV-2 spike protein elicit neutralizing antibodies in COVID-19 patients

Serological responses in patients with severe acute respiratory syndrome coronavirus infection and cross-reactivity with human coronaviruses 229E, OC43, and NL63

Antigenic cross-reactivity between severe acute respiratory syndrome-associated coronavirus and human coronaviruses 229E and OC43

Accurate serology for SARS-CoV-2 and common human coronaviruses using a multiplex approach

Preexisting and de novo humoral immunity to SARS-CoV-2 in humans

The following reagent was produced under HHSN272201400008C and obtained through BEI All authors edited and approved the manuscript.

The authors declare no conflicts of interest.

This study was supported by funding from the Medical Research Council of the Academy of Finland (project numbers 297329 and 336410), Jane and Aatos Erkko Foundation (project numbers 3067-84b53 and 5360-cc2fc), Finnish Cultural Foundation, and the Sigrid Juselius Foundation.

A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t 17 A c c e p t e d M a n u s c r i p t